Lilly Bounces Into ‘Sell in May’ Territory Amid Pricing Pressure
Eli Lilly posts above-consensus Q1 results, lifting shares yet leaving the year-to-date narrative pressured by pricin...
This analysis highlights how long-term returns vary across index funds, emphasizing the impact on portfolio resilience.
28,357 articlesEli Lilly posts above-consensus Q1 results, lifting shares yet leaving the year-to-date narrative pressured by pricin...
Investors are weighing memory constraints and AI demand against Nvidia’s growth potential beyond GPUs as the company ...
Citi initiates BridgeBio at Neutral, signaling caution on ATTR-CM growth despite a strong near-term ramp. The move ad...
A new era of autonomous AI agents could turbocharge voice tech leaders. Learn how agentic will supercharge soundhound...
The Navy's new 30-year shipbuilding plan calls for 15 Trump-Class battleships by 2055, with per-ship costs near $14.5...
An insider move at a biotech stage company can spark questions. This article breaks down the trade, its timing, and w...
Arm Holdings faces a cooling pullback after a strong rally, offering a potential entry point for long-term investors....
A smaller biotech is stealing headlines in 2026 by delivering strong trial results and strategic collaborations. This...
A former Workday executive argues that attitude, authenticity, and relationships—not titles—drive success in an AI er...
As inflation cools, where you retire matters as much as how much you have. This analysis shows how geography changes ...
Many altcoins under $1 could offer outsized gains, but they also carry significant risk. This guide provides a practi...
Retail investors gain broader access to funding startups before IPOs, but the risks and illiquidity demand discipline...